scholarly journals The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer

Cureus ◽  
2021 ◽  
Author(s):  
Maimoona Khushk ◽  
Adil Khan ◽  
Abdur Rehman ◽  
Sehrish Sheraz ◽  
Yar Muhammad Tunio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Cancer Antigen

scholarly journals THE SIGNIFICANCE OF CEA AND CA15-3 IN EARLY BREAST CANCER ITS ASSOCIATION WITH CLINICO PATHOLOGICAL CHARACTERISTICS A SINGLE-CENTER STUDY IN MADINAH, SAUDI ARABIA

2020 ◽  
Vol 8 (11) ◽  
pp. 1082-1087
Author(s):  
Nasser Mulla ◽  
◽  
Yara Bin Saad ◽  
Jamlaa Alharbi ◽  
Salwa Alalwi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Primary Tumor ◽  
Elevated Serum ◽  
Tumor Grade ◽  
Serum Levels ◽  
Clinicopathological Characteristics ◽  
Cancer Antigen ◽  
Cancer Types

Background and Aims: The utility of measuring carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels in patients with breast cancer remains controversial. The present study aims to investigate the association between tumor markers [cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA)] and clinicopathological characteristics. Methods: Serum preoperative CEA and CA 15-3 concentration levels were measured in a total of 135 breast cancer patients.The association of tumor markers levels with clinicopathological characteristics were analyzed. Results: Elevated serum levels of CEA and CA15-3 were identified in 26 (19.26%) and 20 (14.8%) patients, respectively. Increased CEA levels were not associated with age, histological type, tumor size, tumor grade, breast cancer stages, or breast cancer types. CA15-3 levels were positively correlated with the size of the primary tumor (P<0.026) but had no significant correlation with the other factors. Conclusions: The elevation of CA 15-3 was positively correlated with the size of the primary tumor.

Carcinoembryonic antigen and interferon as tumor markers in breast cancer

1983 ◽  
Vol 22 (4) ◽  
pp. 254-256 ◽  
Author(s):  
Yoav Horn ◽  
Dalia Hacohen ◽  
Jacob L. Zeidman ◽  
Natalio Walach ◽  
Sally Sharf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers

scholarly journals Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up

1996 ◽  
Vol 42 (4) ◽  
pp. 564-575 ◽  
Author(s):  
G Sölétormos ◽  
D Nielsen ◽  
V Schiøler ◽  
T Skovsgaard ◽  
P Dombernowsky
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Progressive Disease ◽  
Metastatic Breast ◽  
Tissue Polypeptide Antigen ◽  
First Line ◽  
Cancer Antigen ◽  
Line Chemotherapy

Abstract We investigated whether model systems integrating stochastic variation into criteria for marker assessment could be used for monitoring metastatic breast cancer. A total of 3989 serum samples was obtained from 204 patients receiving first-line chemotherapy and from 112 of these patients during follow-up. Each sample was analyzed for cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen. The efficiency for identifying progression and nonprogression was 94% during therapy and 85% during follow-up, with no false-positive marker results for progressive disease. At clinical progressive disease, the median positive lead time was 35 days during therapy and 76 days during follow-up. Tumor marker assessment may document that a therapy is effective and ought to be continued in spite of adverse toxic effects, and that a treatment is ineffective and should be stopped to prevent unnecessary toxicity. Marker information may also be useful in studies investigating whether early treatment during follow-up will alter the prognosis of metastatic breast cancer.

scholarly journals Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-15 ◽  
Author(s):  
Xuan Li ◽  
Danian Dai ◽  
Bo Chen ◽  
Hailin Tang ◽  
Xiaoming Xie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Carcinoembryonic Antigen ◽  
Histological Grade ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Elevated Serum ◽  
Tumor Type ◽  
Cancer Antigen ◽  
Predictive Values

Purpose. The prognostic role of serum cancer antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) in breast cancer remains controversial. In this study, we conducted a meta-analysis to investigate the prognostic value of these two markers in breast cancer patients.Methods. After electronic databases were searched, 36 studies (31 including information regarding CA15-3 and 23 including information regarding CEA) with 12,993 subjects were included. Based on the data directly or indirectly from the available studies, the hazard ratios (HRs) and odds ratios (ORs) and their 95% confidence intervals (CIs) were pooled according to higher or lower marker levels.Results. Elevated CA15-3 or CEA was statistically significant with poorer DFS and OS in breast cancer (multivariate analysis of OS: HR = 2.03, 95% CI 1.76–2.33 for CA15-3; HR = 1.79, 95% CI 1.46–2.20 for CEA; multivariate analysis of DFS: HR = 1.56, 95% CI 1.06–1.55 for CA15-3; HR = 1.77, 95% CI 1.53–2.04 for CEA). Subgroup analysis showed that CA15-3 or CEA had significant predictive values in primary or metastasis types and different cut-offs and included sample sizes and even the study publication year. Furthermore, elevated CA15-3 was associated with advanced histological grade and younger age, while elevated CEA was related to the non-triple-negative tumor type and older age. These two elevated markers were all associated with a higher tumor burden.Conclusions. This meta-analysis showed that elevated serum CA15-3 or CEA was associated with poor DFS and OS in patients with breast cancer, and they should be tested anytime if possible.

scholarly journals Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer

2010 ◽  
Vol 56 (7) ◽  
pp. 1148-1157 ◽  
Author(s):  
Rafael Molina ◽  
Jose M Auge ◽  
Blanca Farrus ◽  
Gabriel Zanón ◽  
Jaume Pahisa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Primary Breast Cancer ◽  
Disease Free Survival ◽  
Carbohydrate Antigen ◽  
Nodal Involvement ◽  
Total Group ◽  
Ca 15.3

Abstract Background: The utility of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) as prognostic factors in primary breast cancer is unclear. Methods: We prospectively studied CEA and CA 15.3 in the sera of 2062 patients with untreated primary breast cancer diagnosed between 1984 and 2008. Results: Increased CEA (&gt;5 μg/L) and CA 15.3 (&gt;30 kU/L) concentrations were found in 12.7% and 19.6% of the patients, respectively, and 1 or both tumor markers were increased in 28% (570 of 2062). Increases in each tumor marker correlated with larger tumor sizes and nodal involvement. Tumor size, estrogen receptor (ER), and CEA were independent prognostic factors by multivariate analysis in the total group [disease free survival (DFS) and overall survival (OS)] as well as in node-positive (NP) and node-negative (NN) patients. Nodal involvement and histological grade were independent prognostic factors in the total group as well as in NP patients. By contrast, adjuvant treatment and CA 15.3 were independent prognostic factors only in NN patients (DFS and OS). All patients with CEA &gt;7.5 μg/L had recurrence during follow-up. Use of both tumor markers allowed discrimination of the groups of risk in T1 NN patients: 56.3% of recurrences were seen when 1 or both tumor markers were increased, whereas only 9.4% of recurrences were seen in T1 NN patients without increases of either marker. Conclusions: CEA and CA 15.3 are useful prognostic factors in NP and NN breast cancer patients. CEA &gt;7.5 μg/L is associated with a high probability of subclinical metastases.

Serum and Saliva Levels of Cancer Antigen 15-3, Carcinoembryonic Antigen, Estradiol, Vaspin, and Obestatin as Biomarkers for the Diagnosis of Breast Cancer in Postmenopausal Women

2020 ◽  
Vol 51 (6) ◽  
pp. 620-627
Author(s):  
Hyder Farahani ◽  
Jamal Amri ◽  
Mona Alaee ◽  
Fathollah Mohaghegh ◽  
Mohammad Rafiee
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Correlation Coefficients ◽  
Control Group ◽  
Case Group ◽  
Cancer Antigen ◽  
Healthy Women ◽  
Significant Difference ◽  
Serum Cea ◽  
Control Study

Abstract Objective To find suitable biomarkers for diagnosis of Breast cancer in serum and saliva; also, to examine the correlation between salivary and serum concentrations of suitable biomarkers. Methods This case-control study included 30 women with breast cancer as a case group and 30 healthy women as a matched control group. Blood and saliva specimens were collected from all participants. We evaluated serum and salivary cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), estradiol, vaspin, and obestatin concentrations. Mann-Whitney U testing and Spearman correlation coefficients were used for statistical analysis. Results Serum and salivary concentrations of estradiol were significantly higher in patients with breast cancer (BC) than in healthy women (P &lt; .05). Also, serum CEA and salivary obestatin concentrations were significantly higher in BC patients than in the control group (P &lt; .05). However, there was no significant difference between other parameters in patients with BC and controls. We observed a positive correlation between serum and salivary concentrations of CA15-3, as well as a negative correlation between serum and salivary concentrations of vaspin and obestatin. Conclusion The results of this study demonstrated that concentrations of CEA and estradiol in serum, obestatin in serum and saliva, and estradiol in saliva were significantly different between the 2 groups.

Sign in / Sign up

Export Citation Format

Share Document